不同三维剂量验证系统对鼻咽癌容积旋转调强放疗计划的验证价值比较  

Verification value of different three-dimensional dose verification systems for volumetric modulated arc therapy plans of nasopharyngeal carcinoma: a comparative study

作　　者：何勇 王宇 廖雄飞 HE Yong;WANG Yu;LIAO Xiong-fei(Radiotherapy Center,Affiliated Tumor Hospital,School of Medicine,University of Electronic Science and Technology of China,Sichuan Tumor Hospital,Chengdu 610041,Sichuan,China)

机构地区：[1]电子科技大学医学院附属肿瘤医院•四川省肿瘤医院放疗中心,四川成都610041

出　　处：《川北医学院学报》2022年第5期661-664,共4页Journal of North Sichuan Medical College

摘　　要：目的:探究Delta~4、ArcCHECK和EPID EDose 5.0三维剂量验证系统在鼻咽癌容积旋转调强放疗(VMAT)计划剂量验证中的应用价值。方法:将基于Pinnacle治疗计划系统(TPS)制定的127例鼻咽癌VMAT计划,分别利用Delta~4、ArcCHECK和EPID EDose 5.0验证系统进行验证测量,比较三种剂量验证系统的γ通过率、靶区剂量参数和危及器官剂量参数。结果:3%/3 mm标准下,基于三种三维剂量验证系统的γ通过率均>95%,γ通过率比较,差异无统计学意义(P>0.05);2%/3 cmm、2%/2 mm标准下,基于ArcCHECK、EPID EDose 5.0系统的γ通过率高于Delta~4系统(P<0.05)。基于三种三维剂量验证系统计算的靶区(PGTVT、PGTVn、PCTV1和PCTV2)剂量学指标D98%、D2%、Dmean与TPS计算的剂量学指标差异值均<3%,但三种三维剂量验证系统与TPS的靶区剂量学差异比较无统计学意义(P>0.05)。基于三种三维剂量验证系统计算的危及器官剂量学指标Dmax、Dmean与TPS计算的剂量学指标差异值均<3%,三种三维剂量验证系统计算的晶状体、腮腺Dmax与TPS计算的Dmax比较,差异有统计学意义(P<0.05),且ArcCHECK、EPID EDose 5.0小于Delta~4(P<0.05)。结论:Delta~4、ArcCHECK和EPID EDose 5.0三维剂量验证系统在VMAT计划剂量验证中可直观、快速地分析出剂量差异,ArcCHECK和EPID EDose 5.0三维剂量验证系统相对Delta~4更佳。Objective:To explore the application value of three-dimensional dose verification systems(Delta~4,ArcCHECK,EPID EDose 5.0) in the dose verification of volumetric modulated arc therapy(VMAT) plans in nasopharyngeal carcinoma.Methods:127 patients with nasopharyngeal carcinoma undergoing VMAT plan based on Pinnacle Treatment Planning System(TPS) were enrolled.And they were verified by Delta~4,ArcCHECK and EPID EDose 5.0.The γ passing rate, target dose parameters and organ-at-risk dose parameters by the three dose verification systems were compared.Results:Under the standard of 3%/3 mm, γ passing rates based on the three three-dimensional dose verification systems were all over 95%,without significant difference(P>0.05).Under the standards of 2%/3 cmm and 2%/2 mm, γ passing rates based on ArcCHECK and EPID EDose 5.0 were higher than those based on Delta~4(P<0.05).The difference values of D98%,D2% and Dmean in target areas(PGTVT,PGTVn, PCTV1,PCTV2) calculated based on the three three-dimensional dose verification systems and TPS were all lower than 3%,without significant difference(P>0.05).The difference values of Dmax and Dmean calculated based on the three three-dimensional dose verification systems(Delta~4,ArcCHECK,EPID EDose 5.0) and TPS were all lower than 3%.The differences in Dmax of lens and parotid gland, and Dmax between the three three-dimensional dose verification systems and TPS were statistically significant(P<0.05),which were lower based on ArcCHECK and EPID EDose 5.0 than those based on Delta~4(P<0.05).Conclusion:The three-dimensional dose verification systems(Delta~4,ArcCHECK,EPID EDose 5.0) can intuitively and quickly analyze the dose differences in VMAT plan dose verification, ArcCHECK and EPID edose 5.0 three-dimensional dose verification system is better than Delta ~ 4.

关 键 词：鼻咽癌 容积旋转调强放疗 剂量验证 电子射野影像装置 

分 类 号：R739.63[医药卫生—肿瘤] R730.55[医药卫生—临床医学]